Numerai GP LLC Reduces Position in Bruker Co. (NASDAQ:BRKR)

Numerai GP LLC lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 21.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,129 shares of the medical research company’s stock after selling 6,751 shares during the quarter. Numerai GP LLC’s holdings in Bruker were worth $1,414,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of BRKR. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Bruker by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock valued at $779,000 after buying an additional 177 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 196 shares during the last quarter. Insigneo Advisory Services LLC grew its holdings in Bruker by 4.7% during the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company’s stock worth $286,000 after acquiring an additional 218 shares in the last quarter. Arizona State Retirement System increased its position in shares of Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock worth $1,801,000 after purchasing an additional 222 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of Bruker by 5.6% during the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock worth $248,000 after purchasing an additional 223 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BRKR shares. The Goldman Sachs Group lowered their price objective on Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Citigroup decreased their price objective on shares of Bruker from $75.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 7th. Stifel Nicolaus dropped their target price on shares of Bruker from $57.00 to $48.00 and set a “hold” rating on the stock in a report on Thursday, May 8th. Barclays lowered their price objective on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, May 8th. Finally, Wells Fargo & Company decreased their target price on Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, April 17th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.10.

Bruker Price Performance

NASDAQ BRKR opened at $38.74 on Wednesday. The company has a 50-day moving average price of $40.94 and a two-hundred day moving average price of $50.89. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $79.78. The stock has a market cap of $5.87 billion, a price-to-earnings ratio of 50.97, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm had revenue of $801.40 million for the quarter, compared to analysts’ expectations of $763.83 million. During the same period last year, the firm earned $0.53 EPS. The firm’s revenue was up 11.0% compared to the same quarter last year. Analysts forecast that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.52%. Bruker’s payout ratio is 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.